+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?

, : Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?. Human Reproduction Update 19(3): 259-267

BACKGROUND Hematopoietic growth factors (HGFs) are mostly used as supportive measures to reduce infectious complications associated with neutropenia. Over the past decade, the use of HGFs became a common method for mobilizing human CD34+ stem cells, either for autologous or allogeneic transplantation. However, since their introduction the long-term safety of the procedure has become a major focus of discussion and research. Most information refers to healthy normal donors and data concerning pregnant and lactating women are scarce. The clinical question, which is the core of this review, is whether stem cell donation, preceded by administration of granulocyte-colony stimulating factor (G-CSF) for mobilization, is a safe procedure for pregnant donors. METHODS Literature searches were performed in Pubmed for English language articles published before the end of May 2012, focusing on G-CSF administration during pregnancy, lactation and hematopoietic stem cell donation. Searches included animal and human studies. RESULTS Data from animals (n = 15 studies) and women (n = 46 studies) indicate that G-CSF crosses the placenta, stimulates fetal granulopoiesis, improves neonatal survival mostly for very immature infants, promotes trophoblast growth and placental metabolism and has an anti-abortive role. Granulocyte macrophage-CSF is a key cytokine in the maternal immune tolerance towards the implanted embryo and exerts protective long-term programming effects to preimplantation embryos. The available data suggest that probably CSFs should not be administered during the time of most active organogenesis (first trimester), except perhaps for the first week during which implantation takes place. Provided CSF is administered during the second and third trimesters, it appears to be safe, and pregnant women receiving the CSF treatment can become hematopoietic stem cell donors. There are also risks related to the anesthesia, which is required for the bone marrow aspiration. During lactation, there should be a period of at least 3 days to allow for clearance of CSF from milk before resuming breast feeding. With regard to teratogenicity or leukaemogenity, in non-pregnant or non-lactating women reports show that CSF administration is associated with a risk for leukemia; however, this risk is not higher compared with the control population. CONCLUSIONS The information available to date indicates that administration of CSF in general, and G-CSF in particular, is safe and healthy pregnant women can serve as donors of either bone marrow or peripheral blood stem cells. However, the clinical experience is rather limited and therefore until more data become available, G-CSF should not be used during pregnancy and lactation when other therapeutic options, instead of stem cell transplantation, are available.


PMID: 23287427

DOI: 10.1093/humupd/dms053

Other references

Li, N.; Chu, Y.; Yao, L.; Ying, X.; Jiang, H.; Zhou, M.; Xu, C., 2011: A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency. To investigate the effect of a monoclonal antibody (CH12), targeted against epidermal growth factor receptor type III variant (EGFRvIII), on human ovarian cancer cells when administered in combination with cisplatin chemotherapy. Western blot and...

Shevelukha, V.S.; Zaichuk, V.F., 1987: Producing sunflower lines with increased resistance to Sclerotinia. Details are given of selection methods used at the All Union Oil Crops Institute in Krasnodar to produce forms with high resistance to S. sclerotiorum. These involve selection of plants exhibiting resistance to forms of the pathogen attacking part...

Cresswell, H.P.; Kirkegaard, J.A., 1995: Subsoil amelioration by plant roots-the process and the evidence. Current evidence for the potential benefits of biological drilling are reviewed and the constraints to realizing these benefits are discussed. Results are presented from an investigation into biological drilling by rape (Brassica napus) and the su...

Bryssine, G., 1965: Physical properties of tirs of the Gharb. Hypothesis on the formation of tirs (vertisols) are reviewed and their general characteristics are described. A number of profiles, including gray, brown and black tirs, were studied with special reference to their structural condition, both in th...

Plotnikova L.F., 1975: Upper Cretaceous foraminifera of the southern Ukraine. Pages 93-118 1975

Zhai, H-Yuan.; Zhao, C.; Zhang, N.; Jin, M-Na.; Tang, S-An.; Qin, N.; Kong, D-Xin.; Duan, H-Quan., 2012: Alkaloids from Pachysandra terminalis inhibit breast cancer invasion and have potential for development as antimetastasis therapeutic agents. The aim of the present study was to identify potentially useful natural compounds for the development of novel therapeutic agents to inhibit metastasis. A phytochemical investigation of Pachysandra terminalis resulted in the isolation of seven new...

Bardos, D.C., 2005: Probabilistic Gompertz model of irreversible growth. Characterizing organism growth within populations requires the application of well-studied individual size-at-age models, such as the deterministic Gompertz model, to populations of individuals whose characteristics, corresponding to model paramet...

Spur B.; Crea A.; Peters W.; Koenig W., 1983: Synthesis of 11 12 14 15 tetra hydro leukotriene c d e via a. Tetrahedron Letters 24(21): 2135-2136

Filipowski, T.; Rucinska, M.; Kozlowski, L.; Pepinski, W.; Janica, J.; Skawronska, M.; Poznanski, J.; Wojtukiewicz, M., 2001: Loss of heterozygosity on chromosomes 3p, 18q213 and 11p155 as a poor prognostic factor in stage II and III cervical cancer treated by radiotherapy. European Journal of Cancer 37(Supplement 6): S114, October

Wey, M.Chek.; Bendeus, M.; Peng, L.; Hägg, U.; Rabie, A.Bakr.M.; Robinson, W., 2007: Stepwise advancement versus maximum jumping with headgear activator. The aim of this study was to compare the effects of stepwise mandibular advancement versus maximum jumping and extended treatment versus early retention. The material was obtained prospectively and consisted of lateral cephalograms taken at the st...